Article

Iridex receives patent for technology

Iridex Corp. has received a patent for its technology (MicroPulse) designed to provide ophthalmologists with fine dose control of laser energy during eye surgery in patients with glaucoma, diabetic retinopathy, and other retinal disorders.

Mountain View, CA-Iridex Corp. has received a patent for its technology (MicroPulse) designed to provide ophthalmologists with fine dose control of laser energy during eye surgery in patients with glaucoma, diabetic retinopathy, and other retinal disorders.

The technology “enables tissue-sparing photocoagulation, a controlled laser dosing approach [that] induces the long-term benefits of laser procedures with no detectable tissue-damaging side effects,” said Theodore A. Boutacoff, president and chief executive officer of Iridex.

“The company has developed this technology over a number of years using infrared laser systems, and its clinical efficacy has been reported in [more than] 45 peer-reviewed publications,” Boutacoff added. “Extending our [recently patented] technology from our infrared laser systems to our visible laser systems and being granted a patent to protect this proprietary technology for visible laser systems is important because the majority of lasers sold today are visible-wavelength laser systems.”

The newly issued patent describes visible-wavelength lasers capable of delivering laser energy in the form of a user-selectable packet, or train, of discrete pulses rather than merely as a single uninterrupted optical exposure (dose) as offered by visible laser photocoagulators using earlier technology.

Users can adjust all parameters of the recently patented technology, including duration, interpulse interval, and amplitude or, alternatively, can choose a personalized or factory-installed preset to adjust all of these parameters automatically.

The mode for the recently patented technology can be activated or deactivated at the touch of a button, facilitating conventional and the recently patented laser delivery from a single console and delivery device.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.